Baystreet Staff -

Healthnostics Obtains First Bio-Medical Application License Nanoparticle Technology Applies to Several Medical Fields

[ACCESSWIRE]

NEW YORK, NY / ACCESSWIRE / January 14, 2015 / Healthnostics, Inc. (OTC Pink: HNSS) (PINKSHEETS: HNSS), announced it agreed to enter into its first bio-medical license agreement for nanoparticle therapeutic delivery applications. A "nanoparticle" is a particle exhibiting a diameter of 1-100 nanometers (billionths of a meter). The agreement allows Healthnostics to initiate an evaluation, identify ways to utilize the technology, identify development sources and create market applicability. This is the first license entered into under the Company's new Medical Therapeutic Initiative.

This nanoparticle technology is essentially a platform that can increase the efficiency of treatment and the way therapies are delivered for several medical fields. The licensed technology includes patented nanoparticles, nanoparticles producing nitric oxide (NPNO), paramagnetic nanoparticles and related technologies that have a range of applications that have application in dermatology, wound healing and can be applied for oncology purposes. The NPNO application has potential to be applied for the delivery of medical cannabis therapeutics.

About Healthnostics, Inc. (www.healthnostics.com)

Healthnostics is a medical and biotechnology analytics company with the mission of helping improve and participate in the delivery of healthcare by providing information resources for the medical and biotechnology fields.

Forward-Looking Statements

This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

CONTACT:
Healthnostics, Inc.
Investor Relations
contact@healthnostics.com

 

SOURCE: Healthnostics, Inc.